===========================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Amendment No. 1
Under the Securities Exchange Act of 1934
CELL GENESYS, INC.
----------------------------
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
- ---------------------------------------------------------------------------
(Title of Class of Securities)
150921 10 4
-----------------
(CUSIP Number)
December 15, 1999
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ x ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
===========================================================================
Page 1 of 9
Exhibit Index is located at page 8
<PAGE> 2
CUSIP No. 150921 10 4
- ---------------------------------------------------------------------------
1) Name of Reporting Person and its Aventis Pharmaceuticals Inc.
I.R.S. Identification Number 44-0565557
- ---------------------------------------------------------------------------
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
- ---------------------------------------------------------------------------
3) SEC Use Only
- ---------------------------------------------------------------------------
4) Citizenship or Place of Organization Delaware
- ---------------------------------------------------------------------------
5) Sole Voting Power 2,750,000*
Number of ____________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 2,750,000*
Person With ____________________________________________________________
8) Shared Dispositive Power 0
- ---------------------------------------------------------------------------
9) Aggregate Amount Beneficially Owned 2,750,000*
by Each Reporting Person
- ---------------------------------------------------------------------------
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
- ---------------------------------------------------------------------------
11) Percent of Class Represented 8.30%
by Amount in Row (9)
- ---------------------------------------------------------------------------
12) Type of Reporting Person CO
- ---------------------------------------------------------------------------
* Includes up to 750,000 shares that may be purchased for $13.00 per share upon
the exercise of a Common Stock Purchase Warrant during the period beginning
November 27, 1995, and ending October 9, 2000.
<PAGE> 3
CUSIP No. 150921 10 4 13G
- ---------------------------------------------------------------------------
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
- ---------------------------------------------------------------------------
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
- ---------------------------------------------------------------------------
3) SEC Use Only
- ---------------------------------------------------------------------------
4) Citizenship or Place of Organization Delaware
- ---------------------------------------------------------------------------
5) Sole Voting Power 2,750,000*
Number of ____________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 2,750,000*
Person With ____________________________________________________________
8) Shared Dispositive Power 0
- ---------------------------------------------------------------------------
9) Aggregate Amount Beneficially Owned 2,750,000*
by Each Reporting Person
- ---------------------------------------------------------------------------
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
- ---------------------------------------------------------------------------
11) Percent of Class Represented 8.30%
by Amount in Row (9)
- ---------------------------------------------------------------------------
12) Type of Reporting Person CO
- ---------------------------------------------------------------------------
* Includes up to 750,000 shares that may be purchased for $13.00 per share upon
the exercise of a Common Stock Purchase Warrant during the period beginning
November 27, 1995, and ending October 9, 2000.
<PAGE> 4
CUSIP No. 150921 10 4 13G
This Amendment No. 1 to the Statement on Schedule 13G with respect to
the Common Stock of Cell Genesys, Inc. (the "Issuer"), is filed jointly by
Aventis Pharmaceuticals Inc., a Delaware corporation ("Aventis"), and HMR
Pharma, Inc., a Delaware corporation ("Pharma"), to reflect the change of name
of Hoechst Marion Roussel, Inc., to Aventis Pharmaceuticals Inc. The
following items of the Statement on Schedule 13G are hereby amended to read
as follows:
ITEM 2(a). NAME OF PERSON FILING:
- ---------- ----------------------
Aventis Pharmaceuticals Inc.
HMR Pharma, Inc.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
- ---------- ------------------------------------------------------------
Aventis Pharmaceuticals Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
HMR Pharma, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
ITEM 2(c). CITIZENSHIP:
- ---------- ------------
Delaware As To Both Aventis Pharmaceuticals Inc. And
HMR Pharma, Inc.
<PAGE> 5
CUSIP No. 150921 10 4 13G
ITEM 4. OWNERSHIP
- ------- ---------
(a): AMOUNT BENEFICIALLY OWNED:
As Of 10/29/99 2,000,000 Shares Of Common Stock And A Warrant To
Purchase Up To 750,000 Warrant Shares At $13.00 Per Share During The
Period Beginning 11/27/1995 And Ending 10/09/2000.
(b): PERCENT OF CLASS:
8.30%
(c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) Sole power to vote or to direct the vote: 2,750,000
(ii) Shared power to vote or to direct the vote: 0
(iii)Sole power to dispose or to direct the 2,750,000
disposition of:
(iv) Shared power to dispose or to direct the 0
disposition of:
<PAGE> 6
CUSIP No. 150921 10 4 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
AVENTIS PHARMACEUTICALS INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
---------------------------------
Rebecca R. Tilden
Vice President and Secretary
<PAGE> 7
CUSIP No. 150921 10 4 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
HMR PHARMA, INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
-----------------------------
Rebecca R. Tilden
Vice President and
Assistant Secretary
<PAGE> 8
CUSIP No. 150921 10 4 13G
EXHIBIT INDEX
Exhibit No. Description Page No.
- ----------- ------------ ---------
99.A Agreement to File Jointly dated December 9
22, 1999, by and between Aventis
Pharmaceuticals Inc. and HMR Pharma, Inc.
<PAGE> 9
CUSIP No. 150921 10 4 13G
EXHIBIT 99.A
AGREEMENT TO FILE JOINTLY
We, the undersigned, hereby express our agreement that the attached
Schedule 13G is filed on behalf of each of us.
AVENTIS PHARMACEUTICALS INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
-------------------------------
Rebecca R. Tilden
Vice President and Secretary
HMR PHARMA, INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
--------------------------
Rebecca R. Tilden
Vice President and Assistant
Secretary
